title: [Clinical use of 18F-FDG PET/CT in colorectal carcinoma].
abstract: Modern imaging techniques have an important role in the diagnostic procedures of malignancies, and assessing response to therapy. The 18F-FDG PET/CT revolutionized the evaluation of colorectal cancer in terms of preoperative staging and monitoring of recurrence. Conventional imaging techniques have limitations in early assessment of response to therapy. 18F-FDG PET has been shown to allow earlier treatment monitoring, because the metabolic change appears before any anatomic change occurs. The Response Evaluation Criteria in Solid Tumours (RECIST) are widely applied, but they have some limitations. There are new international guidelines for treatment response assessment using PET/CT in solid tumours. The authors review indications and the role of hybrid PET/CT in colorectal cancer.
authors.affiliation: Szent Margit Kórház Onkológiai Osztály Budapest Bécsi út 132. 1032.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Németh
authors.forename: Katalin
authors.initials: K
authors.lastname: Boér
authors.forename: Miklós
authors.initials: M
authors.lastname: Kásler
authors.forename: Katalin
authors.initials: K
authors.lastname: Borbély
mesh_terms: D002277:Carcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000556:secondary / Q000628:therapy; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000556:secondary; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000378:metabolism; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18